Dermatitis Drugs Market Size to Reach US$ 13,630.8 Mn

Posted by Rushikesh Pise on December 3rd, 2019

The Global Dermatitis Drugs Market will expand considerably in the coming years driven by the advancements across numerous drug classes. According to a report published by Fortune Business Insights, titled “Dermatitis Drugs: Global Market Analysis, Insights and Forecast, 2019-2026,” the market was valued at US$ 6,097.4 Mn in 2018. Fortune Business Insights predicts that the market will rise impressively at a CAGR of 10.2% and reach US$ 13,630.8 Mn by the end of 2026.

Browse Complete Report

https://www.fortunebusinessinsights.com/industry-reports/dermatitis-drugs-market-100658

Major Leading Players Mentioned:

  •          Valeant Pharmaceuticals
  •          Astellas Pharma US
  •          Pfizer
  •          Mylan
  •          Bayer
  •          Allergan
  •          LEO Pharma
  •          Regeneron Pharmaceuticals, Inc.
  •          Anacor Pharmaceuticals

The severity of dermatitis has led to an increasing need for efficient drugs. This, in turn, has led to a growing emphasis on the research and development of newer drugs that can be used in compliance with the regulations, enforced by related authorities. Increasing usage approvals will open up numerous windows for the growth of the global market. The report provides an in-depth analysis of various companies that have made significant contributions to the growth of the global dermatitis drugs market.

“Topical Treatment for Atopic Dermatitis gets FDA Nod, Subsequently Aiding the Market’s Expansion”

The global dermatitis drugs market will derive significant growth from increasing usage approvals. In 2017, the Food and Drug Administration passed approval for a new topical treatment for atopic dermatitis. The topical treatment ‘Eucrisa’ was aimed at the treatment of children and adults with mild to moderate atopic dermatitis. The use of Eucrisa to minimize the effects of dermatitis has fueled the demand for the products, across the world. The ability of Eucrisa to act on a body enzyme ‘PDE4’ has created several benefits of the product and this, in turn, will lead to an increase in adoption. After successful clinical trials, Eucrisa was seen to reduce skin rashes, itching, and lichenification. The applications of Eucrisa in the healthcare industry have had a positive impact on the Global Dermatitis Drugs Market and will favor the growth of the market in the coming years. Fortune Business Insights has predicted that growing usage approvals will bode well for the market in the near future.

 

Like it? Share it!


Rushikesh Pise

About the Author

Rushikesh Pise
Joined: November 4th, 2019
Articles Posted: 81

More by this author